NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/13/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization5.03 mln
Float11.17 mln
Earnings Date05/14/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
58.20
Transformational upside
Relative Strength
0
/ 100
Severely lagging
Debt / Equity
0.05
Debt-free
ROE
-1,092
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Reviva Pharmaceuticals Holdings Inc. is a drug development company focused on creating new treatments for patients with limited or no existing options, particularly in brain, lung, heart, and inflammatory conditions. Its main drug candidate, brilaroxazine, is being studied for a wide range of conditions including schizophrenia, depression, Alzheimer's disease, and certain lung diseases, with additional early-stage research into skin conditions. The company is also working on a second drug, RP1208, aimed at treating depression and obesity. Founded in 2018 and based in Cupertino, California, Reviva is working to bring meaningful new medicines to market across several serious health areas.
